No open-market selling at Global Medical REIT Inc. in the past year, which is unusual. Instead two officers and board members bought about $747,000 worth of GMRE.
Decker Mark Okey Jr (CEO) made the biggest buy, worth around $325,000. Notably, at least one C-suite executive was among the buyers.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 3 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Dec 8, 2025 | Decker Mark Okey Jr | CEO | Buy | 10,000 | $32.51 | $325K | SEC |
| Nov 17, 2025 | KIERNAN ROBERT J | CFO | Buy | 3,000 | $31.91 | $96K | SEC |
| Nov 17, 2025 | Decker Mark Okey Jr | CEO | Buy | 4,093 | $32.41 | $133K | SEC |
| Nov 17, 2025 | Decker Mark Okey Jr | CEO | Buy | 5,907 | $32.70 | $193K | SEC |
| Aug 26, 2025 | Cypher Matthew | Director | Buy | 1,350 | $7.38 | $10K | SEC |
| Aug 18, 2025 | Barber Jamie Allen | Executive Officer | Sell | 130,000 | $6.62 | $861K | SEC |
| Aug 18, 2025 | Decker Mark Okey Jr | CEO | Buy | 17,023 | $6.87 | $117K | SEC |
| Aug 18, 2025 | Decker Mark Okey Jr | CEO | Buy | 13,871 | $6.84 | $95K | SEC |
| Jun 25, 2025 | Decker Mark Okey Jr | CEO | Buy | 100,000 | $6.53 | $653K | SEC |
| Jun 25, 2025 | Decker Mark Okey Jr | CEO | Buy | 2,668 | $6.37 | $17K | SEC |
| Jun 25, 2025 | Decker Mark Okey Jr | CEO | Buy | 18,503 | $6.54 | $121K | SEC |
| Jun 25, 2025 | Decker Mark Okey Jr | CEO | Buy | 8,072 | $6.56 | $53K | SEC |
| Jun 25, 2025 | Decker Mark Okey Jr | CEO | Buy | 30,757 | $6.47 | $199K | SEC |
| Jan 10, 2023 | MOORE ROSCOE M JR | Director | Sell | 5,000 | $9.79 | $49K | SEC |
In the last 12 months Global Medical REIT Inc. insiders made open-market purchases worth about $747,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in GMRE was filed on 2025-12-08.
No congressional trades in GMRE were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).